TSPT Key Stats
- Nasdaq stocks posting largest percentage decreases May 22
- Locust Walk Partners Announces Appointment of Chris Ehrlich, Biotechnology Indus... May 14
- TRANSCEPT PHARMACEUTICALS INC Files SEC form 8-K, Other Events May 13
- Transcept Pharmaceuticals downgraded to Hold from Buy at MLV Equity May 10
- Benzinga's Top Downgrades Benzinga May 10
- MLV & Co. Downgrades Transcept Pharmaceuticals (TSPT) to Hold Street Insider May 10
- Transcept Pharma downgraded by MLV & Co May 10
- Transcept: Throwing In The Towel On Intermezzo May 9
- TRANSCEPT PHARMACEUTICALS INC Files SEC form 8-K/A, Costs Associated with Exit o... May 9
- Transcept downgraded to Market Perform from Outperform at JMP Securities May 9
TSPT Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Transcept Pharmaceuticals is down 57.24% over the last year vs S&P 500 Total Return up 27.77%, Cleveland BioLabs up 37.19%, and Vertex Pharmaceuticals up 22.33%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Pro Ratings for TSPT
Pro Report PDF for TSPT
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.Download TSPT Pro Report PDF
Pro Strategies Featuring TSPT
Did Transcept Pharmaceuticals make it into our Pro Portfolio Strategies?